Swedish biotechnology company Cantargia AB (STO:CANTA) on Tuesday released updates on the timelines for the clinical trials of nadunolimab in leukaemia and triple negative breast cancer.
Following US Food and Drug Administration (FDA) approval of a phase 1b/2a clinical trial of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), Cantargia estimates that this trial will commence during the fourth quarter of 2024.
"The remaining steps, including IRB review, are currently in process before the trial can be initiated," said Göran Forsberg, Cantargia CEO.
The first results on safety and short-term efficacy in the ongoing phase 2 clinical trial in triple negative breast cancer, in collaboration with GEICAM, are expected during the first half of 2025.
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Diamyd Medical seeks Fast-Track approval for Type 1 Diabetes immunotherapy
Sun Pharma and Moebius Medical's MM-II receives Fast Track designation for osteoarthritis knee pain
Vivet Therapeutics receives Orphan Drug Designation from European Commission for VTX-806
SFA Therapeutics names new director of Biostatistics
FDA approves Azurity Pharmaceuticals' Nymalize oral solution in 30 mg/5 mL prefilled ENFit syringe